Hopes and challenges: Translational medical research in bladder cancer
Cancer Plus · 2019
DOI: 10.18063/cp.v1i1.189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Plus, 2019. Verfasst von Chong Li und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Bladder cancer is a complex disease and could be classified into non-muscle-invasive or muscle-invasive subtypes according to the distinct genetic background and clinical prognosis. It is necessary to find a non-invasive, economical, and efficient method for the diagnosis and treatment of bladder cancer. Translational medicine provides such an opportunity.Genomics, proteomics, molecular biology, and bioinformatics that aid in studying and exploring the mechanism of bladder cancer development, bladder cancer-related genes, signaling pathways, key molecules, or targets can be clearly used for the diagnosis and treatment of bladder cancer. Biomarkers have been developed as part of a new detection kit for the early screening, diagnosis, and recurrence monitoring of bladder cancer through translational medicine. In addition, targeted drugs and immunological preparations can be used for the treatment of bladder cancer and further improve its existing diagnosis, treatment, and prognosis.
Zitieren
APA
Li, C., Yang, Z., Zhang, X., Kang, X., Yang, Y., Lei, D., Zhao, Y., & Ning, S. (2019). Hopes and challenges: Translational medical research in bladder cancer. Cancer Plus. https://doi.org/10.18063/cp.v1i1.189
Vancouver
Li C, Yang Z, Zhang X, Kang X, Yang Y, Lei D, et al. Hopes and challenges: Translational medical research in bladder cancer. Cancer Plus. 2019. doi:10.18063/cp.v1i1.189
BibTeX
@article{Li2019,
author = {Li, Chong and Yang, Zhao and Zhang, Xu and Kang, Xing and Yang, Yin and Lei, Dechun and Zhao, Yunxia and Ning, Shaojie},
title = {Hopes and challenges: Translational medical research in bladder cancer},
journal = {Cancer Plus},
year = {2019},
doi = {10.18063/cp.v1i1.189}
}
EUVIMED